The FDA this week posted an untitled letter sent Oct. 17 to China-based active pharmaceutical ingredient (API) ...
Eisai has slashed Leqembi's sales forecast by 25% this year, lowering the ceiling for one of the industry's most ...
Amgen and AstraZeneca said on Friday that their asthma drug Tezspire reduced nasal congestion and the size of nasal ...
GSK is leaving the biopharma trade group BIO, a spokesperson confirmed, the latest large pharma to back out of the ...
Nkarta is punting development of a natural killer cell therapy in cancer to focus instead on the same candidate's prospects ...
In another sign that biopharma companies are slowing their early R&D efforts, Charles River Laboratories is shuttering more than a dozen sites. The service provider is working on “consolidating ...
Alan Bash is joining Legend Biotech as its president of Carvykti, an unconventional, newly-created role to oversee the ...
Athira Pharma has shelved a daily drug for Alzheimer’s after a mid-stage flop, instead shifting its focus to an oral ...
Stephen Squinto, recruited by JP Morgan a few years ago to head up its Life Sciences Private Capital team, is raising a ...
The head of AstraZeneca’s operations in China has been detained by authorities there, the company confirmed. Prior to his ...
Gilead said its Covid-19 antiviral Veklury had $692 million in third-quarter sales, far more than the $270 million Wall ...
California voters supported a state ballot measure on Tuesday that would increase oversight around the 340B federal drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback